Transporter-mediated Drug-Drug Interactions, Current Status & Future Perspectives: An ACCP/ISSX Jointly-sponsored Symposium

BASIC SCIENCE OF CLINICAL PHARMACOLOGY TRACK

Offers both CME & CPE Credit
UAN #JA4008220-9999-20-032-H04-P
ACPE – 3.5 CONTACT HOURS/KNOWLEDGE-BASED

CHAIR:
Yanke Yu, PhD, Director, Clinical Pharmacology, Pfizer Inc

TARGET AUDIENCE:
This Symposium will be useful for graduate students, postdoctoral fellows/trainees and professionals in the field of pharmacy, pharmacometrics, clinical pharmacology and clinical pharmacy practice seeking a more in-depth understanding of transporter-mediated drug-drug interactions. This Symposium is applicable to participants across academia, the pharmaceutical industry and regulatory agencies.

GOALS & OBJECTIVES:
Following the completion of this activity, the learner will be able to:
1. Compare different regulatory bodies’ (US Food & Drug Administration, European Medicines Agency) requirements for transporter-mediated drug-drug interactions (DDI);
2. Understand current industrial and regulatory perspective on the role of the animal model, mechanistic static model and physiologically-based pharmacokinetic modeling approaches in prediction and assessment of transporter-mediated DDI;
3. Understand the current status of endogenous transporter biomarkers;
4. Understand the current status of pharmacogenomics of drug transporters.

Overview of Transporter-mediated Drug-Drug Interaction (DDI)
Yanke Yu, PhD, Director, Clinical Pharmacology, Pfizer Inc

Evolution of Regulatory Guidance (US Food & Drug Administration) on Transporter-mediated DDI
Xinning Yang, PhD, Policy Lead, CDER/OTS/OCP, US Food & Drug Administration

European Medicines Agency’s Perspectives on Transporter-mediated DDI
Carolien Versantvoort, PhD, Clinical Pharmacology Assessor, Medicines Evaluation Board, European Medicines Agency

Pharmacogenomics of Drug Transporters & Its Clinical Implication
Kathleen M. Giacomini, PhD, Professor, Univ of California San Francisco

Preclinical Tools to Quantitatively Predict Transporter DDIs: Mechanistic Static Models & In Vivo Animal Models
Manthena Varma, PhD, Associate Research Fellow, Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc

Endogenous Biomarkers for Assessing Transporter-mediated DDIs
Manoli Vourvahis, PharmD, Senior Director, Clinical Pharmacology, Pfizer Inc

Modeling & Simulation of Transporter-mediated DDI: A View from an Industry/Consortium Transporter Focus Group
Venkatesh Pilla Reddy, PhD, Associate Principal Scientist, AstraZeneca plc

The Application of Physiologically-based Pharmacokinetic Modeling in Evaluating Transporter-mediated DDI: A Regulatory Science Perspective
Xinyuan Zhang, PhD, PBPK Lead, Pharmacometrics/OCP/OTS/CDER, US Food & Drug Administration

Faculty Panel Discussion, Questions & Answers, Learner Feedback & Evaluation